Tatsis Ourania's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 14, 2023
- Accession no.
- 0001209191-23-009237
- Filed
- Feb 14, 2023
- Trade date
- Feb 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions. Open-market sales total $82.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tatsis OuraniaCIK 0001789815 | Officer (EVP, Chief Reg. & Quality Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | FTax withholdingDisposed | −1,377 | $294.33 | −$405,292.41 | 69,035 | Direct | |
| Feb 13, 2023 | Common Stock | FTax withholdingDisposed | −2,995 | $298.26 | −$893,288.7 | 66,040 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −2 | $295.84 | −$591.68 | 66,038 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −78 | $298.11F2,F3 | −$23,252.58 | 65,960 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −120 | $298.98F2,F4 | −$35,877.6 | 65,840 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −64 | $299.88F2,F5 | −$19,192.32 | 65,776 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −11 | $300.79 | −$3,308.69 | 65,765 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 3 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53).
Referenced by the price of 1 transaction in Table I.